VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

MF59-adjuvanted SARS-CoV-2 Sclamp vaccine

Vaccine Information

Vaccine Name: MF59-adjuvanted SARS-CoV-2 Sclamp vaccine
Target Pathogen: SARS-CoV-2
Target Disease: COVID-19
Manufacturer: The University of Queensland
Vaccine Ontology ID: VO_0005258
Type: Subunit vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Antigen: The SARS-CoV-2 sclamp antigen comprises a trimeric glycosylated SARS-CoV-2 spike glycoprotein ectodomain fused to a molecular clamp. (Chappell et al., 2021)
Immunization Route: Intramuscular injection (i.m.)

Host Response

References

Chappell et al., 2021: Chappell KJ, Mordant FL, Li Z, Wijesundara DK, Ellenberg P, Lackenby JA, Cheung STM, Modhiran N, Avumegah MS, Henderson CL, Hoger K, Griffin P, Bennet J, Hensen L, Zhang W, Nguyen THO, Marrero-Hernandez S, Selva KJ, Chung AW, Tran MH, Tapley P, Barnes J, Reading PC, Nicholson S, Corby S, Holgate T, Wines BD, Hogarth PM, Kedzierska K, Purcell DFJ, Ranasinghe C, Subbarao K, Watterson D, Young PR, Munro TP. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet. Infectious diseases. 2021; ; . [PubMed: 33887208].